J Drugs Dermatol. 2022 Oct 1;21(10):1129-1132. doi: 10.36849/JDD.6870.
Oral nicotinamide (NAM) supplementation has been shown to decrease the incidence of keratinocyte carcinoma (KC) in high-risk skin cancer patients. NAM is a nicotinamide adenine dinucleotide (NAD+) intermediate and thus directly leads to increased NAD+. This increase in NAD+ is believed to be responsible for NAM’s impact on keratinocyte carcinoma risk. NAD+ has protective cellular effects and is a necessary cofactor for DNA repair, helping to prevent potentially oncogenic mutations. Nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are NAD+ intermediates like NAM; however, their protective roles on cellular DNA and effects on cancer have been under-explored. Research into cellular metabolism and aging suggests that NR and NMN can lead to greater increases in NAD+ vs NAM. NR and NMN are safe and well-tolerated and are consequently currently undergoing investigation as agents able to protect against age-associated disease caused by NAD+ depletion. We hypothesize that oral supplementation with NR or NMN may lead to greater reductions in KC than NAM. J Drugs Dermatol. 2022;21(10): 1129-1132. doi:10.36849/JDD.6870.
口服烟酰胺（NAM）补充剂已被证明可降低高危皮肤癌患者角质细胞癌（KC）的发病率。NAM 是烟酰胺腺嘌呤二核苷酸（NAD+）的中间体，因此直接导致 NAD+增加。据信，NAD+的增加是 NAM 对角质细胞癌风险影响的原因。NAD+具有保护细胞的作用，是 DNA 修复的必要辅助因子，有助于预防潜在的致癌突变。烟酰胺核苷（NR）和烟酰胺单核苷酸（NMN）是与 NAM 一样的 NAD+中间体；然而，它们对细胞 DNA 的保护作用及其对癌症的影响仍未得到充分探索。对细胞代谢和衰老的研究表明，NR 和 NMN 可导致 NAD+的增加幅度大于 NAM。NR 和 NMN 安全且耐受良好，因此目前正在作为能够预防因 NAD+耗竭引起的与年龄相关疾病的药物进行研究。我们假设口服 NR 或 NMN 补充剂可能比 NAM 更能降低 KC 的发病率。J 皮肤病药物杂志。2022；21(10)：1129-1132。doi:10.36849/JDD.6870.
